Insulin Degludec/Liraglutide (Xultophy® 100/3.6): A Comprehensive Clinical Review

Executive Summary

The management of type 2 diabetes mellitus (T2DM) presents a persistent clinical challenge, characterized by a progressive decline in glycemic control that necessitates therapeutic intensification. Traditional intensification pathways often introduce significant burdens, including complex multi-injection regimens, an elevated risk of hypoglycemia, and weight gain, all of which can compromise patient adherence and quality of life.[1] Insulin degludec/liraglutide, marketed as Xultophy® 100/3.6, is a fixed-ratio combination product developed by Novo Nordisk that addresses these challenges by uniting two agents with complementary mechanisms of action: insulin degludec, an ultra-long-acting basal insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.[2]

The therapeutic rationale for this combination is rooted in its ability to target multiple pathophysiological defects of T2DM. Insulin degludec provides stable, peakless, 24-hour basal insulin coverage, primarily addressing fasting plasma glucose (FPG) through a unique mechanism of subcutaneous multi-hexamer depot formation that ensures a slow, continuous release.[3] Concurrently, liraglutide addresses postprandial glucose excursions via glucose-dependent insulin secretion, suppression of glucagon release, and delayed gastric emptying.[3]

Extensive clinical data from the DUAL trial program have consistently demonstrated the potent efficacy of this combination. Across various patient populations—including those inadequately controlled on oral antidiabetic drugs, basal insulin, or GLP-1 RAs—insulin degludec/liraglutide has shown superior or non-inferior reductions in glycated hemoglobin (HbA1c​) compared to its individual components and other standard-of-care regimens.[6] Notably, in the DUAL VII trial, a single daily injection of insulin degludec/liraglutide achieved glycemic control comparable to a multi-injection basal-bolus regimen, but with a significantly lower incidence of hypoglycemia and the added benefit of weight loss versus weight gain.[9]

The safety profile of insulin degludec/liraglutide is consistent with the established profiles of its constituent components. The most common adverse events include hypoglycemia (though at a lower rate than insulin-intensification strategies) and transient gastrointestinal effects such as nausea and diarrhea.[11] The product carries a U.S. Food and Drug Administration (FDA) Boxed Warning regarding a potential risk of thyroid C-cell tumors, a finding based on rodent studies with liraglutide. Consequently, it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[13]

Clinically, insulin degludec/liraglutide is positioned as a highly effective and simplified option for treatment intensification in adults with T2DM. It offers a compelling therapeutic choice for patients who require greater glycemic control than can be achieved with basal insulin or a GLP-1 RA alone, providing a favorable balance of potent efficacy, a reduced risk of key side effects, and a simplified treatment regimen that may enhance long-term adherence.[1]

Pharmacological Profile and Therapeutic Rationale

Component Analysis: Insulin Degludec (Tresiba®)

The development of insulin degludec represents a significant advancement in basal insulin analog technology, designed specifically to overcome the pharmacokinetic and pharmacodynamic limitations of earlier insulins. Its unique properties are a direct result of its molecular structure and subsequent behavior upon subcutaneous administration.

Molecular Structure and Mechanism of Protraction

Insulin degludec is a modified human insulin analog produced via recombinant DNA technology in Saccharomyces cerevisiae.[3] Its structure differs from human insulin by the deletion of the amino acid threonine at position B30 and the addition of a 16-carbon fatty diacid (hexadecanedioic acid) side chain, which is attached to the amino acid lysine at position B29 via a glutamic acid spacer.[3] In its pharmaceutical formulation within the injection pen, which contains zinc and phenol, this molecular structure allows insulin degludec to exist as stable dihexamers.[16]

Upon subcutaneous injection, a novel mechanism of protraction is initiated. The phenol rapidly diffuses away from the injection site, causing the stable dihexamers to lose their conformation and self-assemble into long, soluble multi-hexamer chains.[17] This assembly creates a subcutaneous depot of insulin. Subsequently, zinc ions slowly dissociate from the ends of these multi-hexamer chains, allowing for the very gradual and continuous release of active insulin degludec monomers into the systemic circulation.[17] This multi-hexamer depot formation is the cornerstone of its ultra-long action profile. The evolution from older insulins, which exhibit pronounced peaks and troughs that contribute to glycemic variability and hypoglycemia, to the flat, stable profile of insulin degludec is a critical step forward. This enhanced stability is not merely a pharmacokinetic curiosity; it is the direct mechanism responsible for a key clinical safety advantage: a reduced risk of nocturnal hypoglycemia compared to even first-generation long-acting analogs like insulin glargine U-100.[1]

Pharmacokinetic and Pharmacodynamic (PK/PD) Profile

The unique depot-forming mechanism of insulin degludec results in a remarkably flat and stable PK/PD profile. It has a half-life (t1/2​) exceeding 25 hours and a duration of action that extends beyond 42 hours, allowing for a true once-daily dosing regimen with a steady-state concentration achieved after 2-3 days.[19] This profile is characterized by a near-constant, peakless glucose-lowering effect over a 24-hour period. A key clinical consequence of this stability is a four-fold reduction in day-to-day and within-subject glycemic variability compared to insulin glargine U-100.[18] This predictability provides more consistent glycemic control and is a primary contributor to the lower rates of hypoglycemia, particularly nocturnal hypoglycemia, observed in clinical trials.[19]

Component Analysis: Liraglutide (Victoza®)

Liraglutide is a potent GLP-1 receptor agonist (GLP-1 RA) that mimics the actions of the native incretin hormone GLP-1, addressing multiple pathophysiological defects in T2DM.

GLP-1 Receptor Agonism

Liraglutide is a synthetic analog of human GLP-1, sharing 97% amino acid sequence homology with the endogenous hormone.[3] It exerts its therapeutic effects by binding to and activating GLP-1 receptors, which are expressed in various tissues, including the pancreas, brain, gastrointestinal tract, and heart.[22] This activation triggers a cascade of beneficial metabolic effects:

1. Glucose-Dependent Insulin Secretion: Liraglutide potentiates insulin secretion from pancreatic β-cells in a glucose-dependent manner. This means it primarily stimulates insulin release when blood glucose levels are elevated, thereby minimizing the risk of hypoglycemia when glucose levels are normal or low—a key safety advantage over insulin secretagogues such as sulfonylureas.[21]
2. Glucagon Suppression: It suppresses the secretion of glucagon from pancreatic α-cells, which is often inappropriately elevated in patients with T2DM. This reduction in glucagon leads to decreased hepatic glucose production, further contributing to lower blood glucose levels.[3]
3. Delayed Gastric Emptying: Liraglutide slows the rate of gastric emptying, which delays the absorption of carbohydrates from meals. This action helps to blunt postprandial glucose excursions and contributes to an increased feeling of fullness.[3]
4. Central Appetite Regulation: Liraglutide acts on GLP-1 receptors in the hypothalamus and other brain regions associated with appetite regulation. This central action enhances satiety and reduces hunger, leading to decreased caloric intake and subsequent weight loss.[22]

Pharmacokinetic Advantages

Native human GLP-1 has a very short half-life of approximately 2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).[23] Liraglutide was engineered to overcome this limitation through two key molecular modifications: the substitution of arginine for lysine at position 34, and the attachment of a C16 fatty acid (palmitic acid) via a glutamic acid spacer to the lysine residue at position 26.[3] These changes confer resistance to DPP-4 degradation and enable reversible binding to albumin in the subcutaneous tissue and bloodstream. This albumin binding creates a circulating reservoir, resulting in a significantly prolonged half-life of approximately 13 hours and making it suitable for once-daily administration.[22]

The Fixed-Ratio Combination: Synergistic Action and Rationale

The co-formulation of insulin degludec and liraglutide in a single injection provides a multifaceted and rational approach to T2DM management.

Complementary Mechanisms

The combination leverages the distinct and complementary actions of its two components to achieve comprehensive glycemic control. Insulin degludec provides a stable and continuous basal insulin supply to effectively control fasting plasma glucose by suppressing hepatic glucose output and promoting peripheral glucose uptake.[1] Liraglutide primarily targets postprandial hyperglycemia through its incretin-based mechanisms, while also contributing to fasting glucose control via glucagon suppression.[3] This dual-pronged attack addresses both fasting and post-meal glucose abnormalities, targeting multiple core defects of T2DM in a synergistic manner.[1]

Pharmacokinetic Integrity

Crucially, studies have demonstrated that the individual pharmacokinetic and pharmacodynamic profiles of both insulin degludec and liraglutide are preserved when administered as the fixed-ratio combination product.[1] This ensures that the distinct, beneficial effects of each component are delivered without clinically relevant interference, allowing the ultra-long, flat action of insulin degludec and the once-daily GLP-1 RA effects of liraglutide to be fully realized.

Mitigating Side Effects

The combination is rationally designed to offset the common side effects associated with each component class. The weight gain commonly observed with insulin therapy is counteracted by the weight-loss effect of liraglutide.[1] Furthermore, the risk of hypoglycemia, a primary concern with insulin intensification, is mitigated. This is achieved through the combination of insulin degludec's stable, peakless profile and liraglutide's glucose-dependent mechanism of action, resulting in a lower overall hypoglycemia risk compared to intensifying with higher doses of basal insulin or advancing to a basal-bolus regimen.[1] From a tolerability standpoint, initiating therapy with the combination product may also reduce the incidence or severity of gastrointestinal side effects, such as nausea, compared to initiating a standalone GLP-1 RA at its full therapeutic dose.[1] The value of this combination extends beyond enhanced efficacy; it represents a significant step toward treatment simplification. In T2DM, the progression from oral agents to basal insulin and then to complex multi-injection regimens is a major source of treatment burden, negatively impacting adherence and quality of life.[1] By delivering the efficacy of an intensified regimen in a single daily injection, insulin degludec/liraglutide addresses a critical patient-centric barrier to effective long-term disease management.[6]

Evidence of Clinical Efficacy: The DUAL Trial Program

The efficacy and safety of insulin degludec/liraglutide have been extensively evaluated in the DUAL (Dual Action of Liraglutide and Insulin Degludec) clinical trial program. This series of phase 3 trials investigated the combination across a wide spectrum of patients with T2DM, establishing its clinical utility at various stages of the treatment continuum. The consistent performance of insulin degludec/liraglutide across these diverse clinical scenarios—from insulin-naïve patients to those failing complex regimens—demonstrates its versatility as an intensification strategy, positioning it not as a niche product but as a broadly applicable therapeutic tool.[8]

Glycemic Control Across the Treatment Continuum

In Insulin-Naïve Patients (DUAL I)

The DUAL I trial enrolled insulin-naïve patients with T2DM inadequately controlled on one or more oral antidiabetic drugs (OADs). The trial compared the fixed-ratio combination to its individual components administered alone. After 26 weeks, insulin degludec/liraglutide demonstrated a statistically significant superior reduction in HbA1c​ compared to liraglutide alone (estimated treatment difference: -0.64%; p<0.0001) and was non-inferior to insulin degludec alone.[6] These results confirmed the potent glucose-lowering capacity of the combination and the additive benefit of including basal insulin for patients failing OADs.

Intensification from Basal Insulin (DUAL II & DUAL V)

Two key trials established the efficacy of insulin degludec/liraglutide as an intensification strategy for patients already on basal insulin.

• DUAL II: In patients inadequately controlled on basal insulin, switching to insulin degludec/liraglutide resulted in a superior HbA1c​ reduction compared to continuing on insulin degludec alone (with the insulin degludec dose capped at 50 units in both arms). The ETD was -1.1% (p<0.0001), highlighting the substantial glycemic contribution of the liraglutide component in this patient population.[6]
• DUAL V: This trial compared insulin degludec/liraglutide against uptitration of insulin glargine U-100 in patients uncontrolled on 20-50 units of insulin glargine. Insulin degludec/liraglutide again demonstrated superior HbA1c​ reduction, proving its value as a more effective intensification option than simply increasing the dose of basal insulin.[8]

Intensification from GLP-1 RA Therapy (DUAL III)

The DUAL III trial focused on patients inadequately controlled on a maximum dose of a GLP-1 RA (liraglutide or exenatide) plus OADs. Patients were randomized to either switch to insulin degludec/liraglutide or continue their existing GLP-1 RA therapy. The switch to the combination product resulted in a markedly superior HbA1c​ reduction, with mean HbA1c​ falling from 7.8% to 6.4% in the combination group, compared to a modest change from 7.7% to 7.4% in the group that continued on the GLP-1 RA alone (ETD: -0.94%; p<0.001).[8] This trial validated the clinical utility of insulin degludec/liraglutide for patients who are not at goal on GLP-1 RA therapy.

Comparison to Basal-Bolus Therapy (DUAL VII)

DUAL VII was a pivotal trial that compared the efficacy and safety of once-daily insulin degludec/liraglutide against a full basal-bolus insulin regimen (once-daily insulin glargine U-100 plus mealtime insulin aspart) in patients uncontrolled on basal insulin. After 26 weeks, insulin degludec/liraglutide was shown to be non-inferior in terms of HbA1c​ reduction, with both groups achieving a mean reduction of -1.5%.[9] This finding is particularly significant because it demonstrates that a simplified, single-injection regimen can achieve the same level of glycemic control as a complex, multi-injection gold-standard therapy. This challenges the traditional intensification paradigm, suggesting that for many patients, the burdens and risks of basal-bolus therapy can be avoided or delayed without sacrificing glycemic efficacy.[1]

Use as Add-on to SGLT-2 Inhibitors (DUAL IX)

Reflecting the evolving landscape of T2DM treatment, the DUAL IX trial investigated insulin degludec/liraglutide as an add-on therapy for patients inadequately controlled on a sodium-glucose cotransporter-2 (SGLT-2) inhibitor. The combination product demonstrated superior HbA1c​ reduction compared to adding insulin glargine U-100 (-1.94% vs. -1.68%; p<0.0001), confirming its efficacy when used in conjunction with newer classes of oral agents.[32]

Impact on Key Secondary Outcomes

Body Weight

A consistent and clinically important finding across the DUAL program was the favorable effect of insulin degludec/liraglutide on body weight, a key differentiator from traditional insulin intensification.

• Versus Insulin Alone: When compared to basal insulin monotherapy (degludec or glargine), the combination product consistently led to weight loss or mitigated weight gain. In DUAL VII, patients treated with insulin degludec/liraglutide experienced a mean weight loss of 0.9 kg, in stark contrast to a mean weight gain of 2.6 kg in the basal-bolus group.[9] Similarly, in DUAL IX, patients on the combination had no change in body weight, whereas those on insulin glargine U-100 gained an average of 2.0 kg.[32]
• Versus Liraglutide Alone: It is important to note that while advantageous compared to insulin, the combination resulted in less weight loss than liraglutide alone in the DUAL I trial (-0.5 kg vs. -3.0 kg), reflecting the anabolic effect of the insulin component.[6]

Hypoglycemia Risk

Insulin degludec/liraglutide demonstrated a significantly improved hypoglycemia safety profile compared to insulin-based intensification strategies.

• Versus Basal-Bolus Therapy: In the DUAL VII trial, the rate of severe or blood glucose-confirmed symptomatic hypoglycemic events was 89% lower in the insulin degludec/liraglutide arm compared to the basal-bolus arm (1.1 vs. 8.2 events per patient-year of exposure, respectively; p<0.0001).[9] This dramatic reduction in hypoglycemia, despite achieving the same glycemic target, is a cornerstone of the product's value proposition.
• Versus Basal Insulin Uptitration: In DUAL IX, the rate of hypoglycemia was 58% lower with insulin degludec/liraglutide than with uptitrated insulin glargine U-100.[32]

The table below summarizes the key efficacy outcomes from selected pivotal DUAL trials.

Table 1: Summary of Key DUAL Clinical Trials

Trial Identifier	Patient Population/Prior Therapy	Comparator Arm(s)	Mean Baseline HbA1c​ (%)	Change in HbA1c​ (ETD vs. Comparator)	Change in Body Weight (ETD vs. Comparator)	Rate of Confirmed Hypoglycemia (Rate Ratio vs. Comparator)
DUAL I 6	Insulin-naïve, on OADs	Insulin Degludec	8.3	-0.47% (p<0.0001)	-2.22 kg (p<0.0001)	0.68 (p<0.05)
		Liraglutide	8.3	-0.64% (p<0.0001)	+2.44 kg (p<0.0001)	7.61 (p<0.0001)
DUAL II 6	On basal insulin	Insulin Degludec	8.8	-1.1% (p<0.0001)	-2.5 kg (p<0.0001)	Not specified
DUAL VII 9	On basal insulin	Basal-Bolus (IGlar U-100 + IAsp)	8.2	Non-inferior	-3.57 kg (p<0.0001)	0.11 (p<0.0001)
DUAL IX 32	On SGLT-2i ± OADs	Insulin Glargine U-100	Not specified	-0.26% (p<0.0001)	-2.0 kg (p-value not specified)	0.42 (p=0.0035)
ETD: Estimated Treatment Difference; OADs: Oral Antidiabetic Drugs; IGlar U-100: Insulin Glargine 100 units/mL; IAsp: Insulin Aspart.

Cardiovascular Profile

While no dedicated cardiovascular outcomes trial (CVOT) has been conducted for the fixed-ratio combination product itself, the cardiovascular safety and benefits of its individual components are well-established through large, randomized, placebo-controlled trials.[34]

• LEADER Trial (Liraglutide): The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial demonstrated that liraglutide (at a dose of 1.8 mg) significantly reduced the risk of the primary composite endpoint of major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, compared to placebo in patients with T2DM and high cardiovascular risk.[34]
• DEVOTE Trial (Insulin Degludec): The Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) established the cardiovascular safety of insulin degludec, demonstrating non-inferiority to insulin glargine U-100 for the incidence of MACE in a similar high-risk population.[34]

The cardiovascular benefits of the combination product are therefore inferred from its components. It is important to recognize that the proven cardioprotective dose of liraglutide used in the LEADER trial was 1.8 mg. This dose is only achieved in patients who are titrated to the maximum daily dose of 50 units of insulin degludec/liraglutide.[13] Patients on lower doses receive a proportionally smaller amount of liraglutide, and the MACE reduction benefit cannot be directly extrapolated to them. However, post-hoc analyses of the DUAL II and DUAL V trials did show that treatment with insulin degludec/liraglutide led to statistically significant improvements in several cardiovascular risk markers compared to basal insulin alone, including reductions in systolic blood pressure, total cholesterol, and LDL cholesterol. A small but significant increase in heart rate was also observed, which is a known class effect of GLP-1 RAs.[29]

Clinical Application: Dosing and Administration

The effective and safe use of insulin degludec/liraglutide requires a clear understanding of its specific dosing, titration, and administration protocols. The product's fixed-ratio nature necessitates a structured approach to initiation and adjustment.

Dosing Regimen

Dosage Form and Strength

Insulin degludec/liraglutide is marketed as Xultophy® 100/3.6 and is available as a sterile, clear, and colorless solution in a 3 mL single-patient-use pre-filled disposable pen. Each milliliter (mL) of the solution contains 100 units of insulin degludec and 3.6 milligrams (mg) of liraglutide.[38]

Dose Steps

The medication is dosed in "dose steps," where the number displayed in the pen's dose counter corresponds to the number of units of insulin degludec. Each single dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide. The pen is designed to deliver doses ranging from a minimum of 10 units to a maximum of 50 units, in increments of one unit.[6]

Recommended Starting Doses

The recommended starting dose is tailored to the patient's prior antidiabetic therapy, a strategy designed to balance the need for an effective starting dose with the goal of minimizing gastrointestinal side effects from the liraglutide component. For patients new to GLP-1 RA therapy, a more gradual introduction to liraglutide is warranted to enhance tolerability. Conversely, patients already experienced with injectable therapies may tolerate and benefit from a higher initial dose.

• For Patients Naïve to Basal Insulin or a GLP-1 RA: The recommended starting dose is 10 units (containing 10 units of insulin degludec and 0.36 mg of liraglutide) injected subcutaneously once daily.[13]
• For Patients Converting from Basal Insulin or a GLP-1 RA: It is imperative to discontinue the previous basal insulin or GLP-1 RA therapy prior to initiation. The recommended starting dose for this population is 16 units (containing 16 units of insulin degludec and 0.58 mg of liraglutide) injected subcutaneously once daily.[13]

Dose Titration

Following initiation, the dose should be adjusted based on the patient's individual metabolic needs and glycemic targets, guided by self-monitored fasting plasma glucose (FPG) readings. The recommended titration schedule is an adjustment of 2 units, either upwards or downwards, every 3 to 4 days (i.e., once or twice weekly) until the desired FPG target is achieved.[38]

Maximum Dose

The maximum approved daily dose of Xultophy® 100/3.6 is 50 units. This corresponds to a delivery of 50 units of insulin degludec and 1.8 mg of liraglutide.[13] Patients who require a daily dose persistently above 50 units to achieve glycemic control should be transitioned to an alternative antidiabetic therapy, as the fixed-ratio combination cannot accommodate higher insulin requirements without exceeding the maximum recommended dose of liraglutide.[38]

The table below provides a practical summary of the dosing and titration protocol.

Table 2: Dosing and Titration Guide for Xultophy® 100/3.6

Patient Status	Recommended Starting Dose (Dose Steps)	Component Doses	Titration Schedule	FPG Reading vs. Target	Recommended Dose Adjustment
Naïve to Basal Insulin or GLP-1 RA	10 units	10 units insulin degludec / 0.36 mg liraglutide	Every 3-4 days (Once or Twice Weekly)	Above Target	+2 units
Converting from Basal Insulin or GLP-1 RA	16 units	16 units insulin degludec / 0.58 mg liraglutide		Within Target	0 units
				Below Target	-2 units
FPG: Fasting Plasma Glucose. The patient-specific FPG target should be determined by the prescribing clinician.

Administration and Handling

Administration Instructions

Proper administration technique is crucial for efficacy and safety.

• Timing: Administer once daily at approximately the same time each day. It can be taken with or without food.[13]
• Injection Site: The injection should be administered subcutaneously into the thigh, upper arm, or abdomen. It must not be administered intravenously or intramuscularly.[13]
• Site Rotation: Patients must be instructed to rotate injection sites within the same anatomical region (e.g., different locations on the abdomen) with each dose. This practice is essential to reduce the risk of developing lipodystrophy (pitting or thickening of the skin) and localized cutaneous amyloidosis (lumps under the skin), both of which can impair insulin absorption.[13]
• Pen Use: The Xultophy® 100/3.6 pen is for single-patient use only and must never be shared with others, even if the needle is changed, due to the risk of transmitting blood-borne pathogens.[39] A new needle (e.g., NovoFine® or NovoTwist®) must be used for each injection and should be removed and disposed of properly after use.[40]

Storage

• Unopened Pens: Should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). They should not be frozen; if a pen has been frozen, it must be discarded.[51]
• Pen in Use: Once in use, a pen can be stored for up to 21 days either at room temperature (below 30°C or 86°F) or in a refrigerator. It should be protected from direct heat and light.[51]

Management in Special Scenarios

Missed Doses

The protocol for a missed dose is designed to prevent hypoglycemia from "dose stacking."

• If a dose is missed, the patient should skip that dose and take their next dose at the regularly scheduled time. They should not take an extra dose or increase the subsequent dose to compensate.[39]
• If more than three consecutive days have elapsed since the last dose, the patient should contact their healthcare provider. It is recommended to re-initiate therapy at the appropriate starting dose (10 or 16 units) to mitigate the risk of gastrointestinal side effects associated with re-introducing liraglutide after a washout period.[39] This specific recommendation is driven by the pharmacodynamics of the liraglutide component; tolerance to its GI effects can diminish after a break in therapy, and restarting at a higher maintenance dose could precipitate significant nausea and vomiting.[54]

Special Populations

• Geriatric Patients: No overall differences in safety or effectiveness were observed, but initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions, which may be more difficult to recognize in the elderly.[38]
• Renal Impairment: The product has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min). Postmarketing reports for liraglutide have noted cases of acute renal failure. Therefore, use in patients with renal impairment requires caution and more intensive glucose monitoring.[38]
• Hepatic Impairment: There is limited experience in patients with hepatic impairment. Use with caution and intensified glucose monitoring is recommended.[48]

Comprehensive Safety and Tolerability Profile

The safety profile of insulin degludec/liraglutide is a composite of the known effects of its two components. While generally well-tolerated, it is associated with several important warnings, precautions, and potential adverse reactions that require careful consideration and patient counseling.

Boxed Warning: Risk of Thyroid C-Cell Tumors

Insulin degludec/liraglutide carries a Boxed Warning from the U.S. FDA, its most stringent warning, regarding the risk of thyroid C-cell tumors.[13]

• Preclinical Evidence: This warning is predicated on preclinical toxicology studies in which liraglutide, one of the active components, was shown to cause a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (both benign adenomas and malignant carcinomas) in rats and mice at clinically relevant exposures.[13]
• Uncertain Human Relevance: The direct relevance of these rodent findings to humans remains unknown and is a subject of ongoing debate. A key biological difference is that rodent thyroid C-cells express a high density of GLP-1 receptors, whereas healthy human C-cells express few, if any. However, some human medullary thyroid carcinomas (MTCs) have been found to express GLP-1 receptors, leaving a degree of uncertainty.[13]
• Clinical Implications and Contraindications: Due to this potential risk, the medication is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic disorder that predisposes individuals to MTC.[13] This warning fundamentally shapes the drug's clinical application, making it imperative for clinicians to conduct a thorough personal and family history screening before prescribing. Furthermore, all patients must be counseled on the potential risk and informed of the symptoms of thyroid tumors, such as a new neck mass, dysphagia (difficulty swallowing), dyspnea (shortness of breath), or persistent hoarseness.[13] The FDA has determined that routine monitoring with serum calcitonin measurements or thyroid ultrasound is of uncertain value for the early detection of MTC in this context.[13]

Adverse Reactions

Common Adverse Events

The most frequently reported adverse reactions (≥5% incidence) in clinical trials are generally mild to moderate in severity and include [12]:

• Nasopharyngitis (up to 10%)
• Headache (9%)
• Nausea (8%)
• Diarrhea (8%)
• Increased lipase (7%)
• Upper respiratory tract infection (6%)

Hypoglycemia

As with any insulin-containing product, hypoglycemia is the most common adverse reaction.[11] While clinical trials demonstrated a lower risk of hypoglycemia with insulin degludec/liraglutide compared to basal-bolus therapy, it remains a significant clinical consideration, with some trials reporting events in up to 37% of participants.[9] Severe hypoglycemia can lead to seizures, coma, and can be life-threatening.[49]

Gastrointestinal Effects

Nausea, vomiting, and diarrhea are common, particularly upon treatment initiation or dose escalation. These effects are primarily attributable to the liraglutide component and are typically transient.[11] If severe and persistent, these GI events can lead to dehydration, which may precipitate or worsen renal impairment.[46]

Injection Site Reactions

Local reactions at the injection site, such as redness, swelling, pain, itching, and bruising, may occur. Continuous rotation of injection sites is crucial to prevent the development of lipodystrophy or localized cutaneous amyloidosis, which can interfere with insulin absorption.[13]

Other Serious Warnings and Precautions

The safety profile of insulin degludec/liraglutide is a predictable composite of the known risks of its components. Clinicians familiar with modern basal insulins and GLP-1 RAs can anticipate and manage these risks effectively, as the combination does not appear to introduce novel safety signals beyond those of its constituents.

• Pancreatitis: Postmarketing reports have documented cases of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, with liraglutide use. Patients should be instructed to seek immediate medical care for persistent, severe abdominal pain, which may radiate to the back. If pancreatitis is suspected, the medication must be discontinued promptly and not restarted if the diagnosis is confirmed.[13]
• Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, sometimes requiring hemodialysis, in patients treated with liraglutide. These events are often associated with dehydration secondary to severe nausea, vomiting, or diarrhea. Patients should be advised on the importance of maintaining adequate hydration.[13]
• Acute Gallbladder Disease: The use of GLP-1 RAs has been associated with an increased risk of acute gallbladder disease, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation). If gallbladder disease is suspected based on symptoms like severe upper abdominal pain or jaundice, appropriate diagnostic studies are indicated.[13]
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergic reactions, including anaphylaxis and angioedema, can occur. The medication should be discontinued immediately if such a reaction is suspected. Caution is advised when prescribing to patients with a history of angioedema with other GLP-1 RAs, as a predisposition to this reaction cannot be ruled out.[13]
• Hypokalemia: All insulin products, including insulin degludec, facilitate the shift of potassium from the extracellular to the intracellular space. This can lead to hypokalemia, which, if untreated, may cause respiratory paralysis, ventricular arrhythmias, and death. Potassium levels should be monitored in patients at risk, such as those on potassium-lowering medications.[13]
• Fluid Retention and Heart Failure: Co-administration with thiazolidinediones (TZDs) can cause fluid retention, which may lead to or exacerbate heart failure. Patients should be monitored for signs and symptoms of heart failure (e.g., shortness of breath, rapid weight gain, edema) if this combination is used.[17]

Contraindications

Insulin degludec/liraglutide is absolutely contraindicated in the following situations:

• Patients with a personal or family history of MTC or MEN 2.[13]
• During episodes of hypoglycemia.[13]
• Patients with a history of a serious hypersensitivity reaction to insulin degludec, liraglutide, or any of the product's excipients.[13]
• It is not indicated for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (DKA).[13]

Drug Interactions and Disease State Considerations

The therapeutic effect of insulin degludec/liraglutide can be significantly altered by concomitant medications and underlying patient comorbidities. A thorough review of a patient's medication list and medical history is essential prior to initiation and during treatment.

Pharmacodynamic Interactions (Affecting Glycemic Control)

Numerous drugs can interact with insulin degludec/liraglutide by altering glucose metabolism, necessitating dose adjustments and more frequent blood glucose monitoring. While the list of potential interactions is long, most can be managed with standard clinical vigilance. However, the interaction with alcohol is particularly critical due to its unpredictable and potentially severe impact. Acute alcohol consumption can inhibit hepatic gluconeogenesis, significantly increasing the risk of severe hypoglycemia, especially in a fasted state.[38] Conversely, chronic use or the caloric content of alcoholic beverages can worsen glycemic control.[38] This dual, unpredictable effect makes patient education on avoiding or strictly limiting alcohol a high-priority safety intervention.

Another interaction of paramount importance involves drugs that can mask the symptoms of hypoglycemia, particularly non-selective beta-blockers. Adrenergic symptoms like tachycardia, tremors, and anxiety are the primary early warning signs of hypoglycemia that patients learn to recognize.[49] Beta-blockers can blunt or eliminate these signs, leaving the patient unaware of their falling blood glucose until they develop more severe neuroglycopenic symptoms like confusion, seizure, or coma.[38] This effectively removes the patient's primary physiological defense against a severe adverse event, elevating the risk substantially.

The table below categorizes major drug interactions based on their clinical effect.

Table 3: Clinically Significant Drug Interactions with Xultophy® 100/3.6

Interacting Drug/Class	Effect on Glycemic Control	Putative Mechanism	Clinical Recommendation/Monitoring
Drugs that Increase Hypoglycemia Risk
Other Antidiabetic Agents (e.g., Sulfonylureas, SGLT-2i)	↑ Hypoglycemia Risk	Pharmacodynamic synergism	Consider dose reduction of the concomitant agent (especially sulfonylureas). Increase frequency of blood glucose monitoring.13
ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs)	↑ Hypoglycemia Risk	May improve insulin sensitivity	Increase frequency of blood glucose monitoring. Dosage adjustment may be needed.13
Salicylates (high dose, e.g., >3 g/day aspirin)	↑ Hypoglycemia Risk	Pharmacodynamic synergism	Increase frequency of blood glucose monitoring. Insulin dose adjustment may be required.13
Fibrates, Fluoxetine, MAOIs	↑ Hypoglycemia Risk	Various mechanisms	Increase frequency of blood glucose monitoring. Dosage adjustment may be needed.13
Drugs that Decrease Efficacy (Hyperglycemia Risk)
Corticosteroids, Atypical Antipsychotics, Thiazide Diuretics	↓ Efficacy	Pharmacodynamic antagonism, insulin resistance	Increase frequency of blood glucose monitoring. Dosage increase of Xultophy® may be needed.13
Sympathomimetic Agents (e.g., albuterol), Thyroid Hormones	↓ Efficacy	Hormonal counter-regulation	Increase frequency of blood glucose monitoring. Dosage increase of Xultophy® may be needed.13
HIV Protease Inhibitors	↓ Efficacy	Induce insulin resistance	Increase frequency of blood glucose monitoring. Dosage increase of Xultophy® may be needed.13
Drugs with Variable Effects or that Mask Hypoglycemia
Alcohol	↑ or ↓ Effect	↑ Hypoglycemia risk (inhibits gluconeogenesis); ↑ Hyperglycemia risk (calories)	Avoid or strictly limit alcohol consumption. Counsel patient on risks of delayed hypoglycemia.38
Beta-blockers (especially non-selective)	↑ or ↓ Effect; Masks Symptoms	May cause hyper- or hypoglycemia; blocks adrenergic warning signs of hypoglycemia (tachycardia, tremors)	Counsel patient on the risk of masked hypoglycemia and the importance of relying on blood glucose monitoring rather than symptoms. Increase monitoring frequency.13
Clonidine, Reserpine, Guanethidine	Masks Symptoms	Blocks adrenergic warning signs of hypoglycemia	Counsel patient on the risk of masked hypoglycemia. Increase monitoring frequency.13

Pharmacokinetic Interactions (Delayed Gastric Emptying)

The liraglutide component of the combination product causes a delay in gastric emptying. This has the theoretical potential to affect the rate and extent of absorption of concomitantly administered oral medications.[25] While dedicated pharmacokinetic studies with liraglutide did not find clinically significant alterations in the absorption of several commonly used drugs (including acetaminophen, atorvastatin, lisinopril, digoxin, and oral contraceptives), caution is still advised, particularly for medications with a narrow therapeutic index where changes in absorption could have significant clinical consequences.[13]

Disease State Interactions

Certain underlying medical conditions can increase the risks associated with insulin degludec/liraglutide therapy.

• Pancreatitis: Given the association between GLP-1 RAs and pancreatitis, the medication should be used with extreme caution, if at all, in patients with a history of pancreatitis.[5]
• Gastroparesis: The medication is not recommended for patients with diabetic gastroparesis or other severe gastrointestinal motility disorders, as the gastric-slowing effect of liraglutide could exacerbate these conditions.[14]
• Renal and Hepatic Impairment: Patients with renal or hepatic impairment may be at a higher risk of hypoglycemia due to altered drug clearance. The product has not been studied in patients with severe renal impairment (eGFR <30 mL/min/1.73m2) and should be used with caution and intensified glucose monitoring in those with mild to moderate impairment.[38]
• Depression and Suicidal Ideation: Suicidal thoughts and behaviors have been reported in clinical trials with other weight management products. While a direct causal link with liraglutide is not established, it is a precaution for the class, and patients should be monitored for any changes in mood or the emergence of suicidal ideation.[70]

Patient Counseling and Education

Effective patient counseling is a cornerstone of safe and successful therapy with insulin degludec/liraglutide. Education should be comprehensive, covering not only the mechanics of administration but also the critical safety information and self-management strategies. This counseling should be viewed as a primary risk mitigation strategy, empowering the patient to become an active participant in their own safety.

Core Safety Counseling

• Thyroid Tumor Risk: Patients must be counseled on the FDA Boxed Warning. This includes explaining that while the risk in humans is not confirmed, it is a potential concern based on animal studies. They should be explicitly taught the symptoms of a potential thyroid tumor (e.g., a new lump or swelling in the neck, persistent hoarseness, difficulty swallowing, or shortness of breath) and instructed to report any such symptoms to their provider immediately. It is also essential to confirm and document that the patient has no personal or family history of MTC or MEN 2.[13]
• Pancreatitis Risk: Patients should be informed about the signs and symptoms of acute pancreatitis, particularly the hallmark symptom of persistent, severe abdominal pain that may radiate to the back, with or without vomiting. They must understand the importance of discontinuing the medication and seeking immediate medical evaluation if these symptoms occur.[13]
• Hypoglycemia Recognition and Management:
• Recognition: Patients need to be thoroughly educated on the signs and symptoms of hypoglycemia. These can be categorized into adrenergic symptoms (shakiness, sweating, anxiety, palpitations, hunger) and neuroglycopenic symptoms (confusion, drowsiness, blurred vision, slurred speech, seizure, loss of consciousness). It is important to explain that in long-standing diabetes or with the use of certain drugs like beta-blockers, the early adrenergic warning signs may be diminished or absent.[14]
• Management: Patients should be instructed to always have a source of fast-acting carbohydrate (e.g., glucose tablets, fruit juice, non-diet soda, hard candy) readily available. The "Rule of 15" (consume 15 grams of carbohydrate, wait 15 minutes, and re-check blood glucose) is a simple and effective management strategy for mild-to-moderate episodes. For severe hypoglycemia where the patient is unable to self-treat, a family member, caregiver, or colleague should be trained on how to administer a glucagon emergency kit.[14]

Device Use and Administration Technique

• Pen Instructions: Patients should receive hands-on training with a demonstration pen. Key steps to emphasize include: washing hands, visually inspecting the solution to ensure it is clear and colorless, attaching a new needle for every injection, priming the pen before each dose to ensure flow (the "air shot"), correctly dialing the prescribed dose, and performing the injection.[52]
• Injection Technique: The proper technique for a subcutaneous injection into the abdomen, thigh, or upper arm should be demonstrated. The critical importance of rotating injection sites must be stressed to prevent lipodystrophy and localized cutaneous amyloidosis, which can impair absorption and lead to erratic glycemic control.[15]
• Safety Checks: Patients must be instructed to always check the pen label before each injection to prevent accidental mix-ups with other insulin products. The warning to never share pens or needles with another person, even if the needle is changed, must be delivered emphatically to prevent the transmission of blood-borne pathogens. While this is standard for all injectables, the convenience of a pen device may lead to a casual attitude, making this warning particularly crucial.[44]

Lifestyle and Management Considerations

• Missed Doses: The protocol for a missed dose should be clear: skip the missed dose and take the next dose at the regularly scheduled time. Patients should not "double up" on doses. If more than three days are missed, they must contact their healthcare provider before restarting, as a lower re-initiation dose will likely be required to avoid gastrointestinal side effects.[40]
• Diet, Exercise, and Illness: Patients should understand that their insulin needs can change with variations in meal patterns (timing or macronutrient content), physical activity levels, or during periods of acute illness. These situations require more frequent blood glucose monitoring and may necessitate a temporary dose adjustment in consultation with their provider.[38]
• Alcohol Consumption: Given the unpredictable and potentially dangerous effects of alcohol on blood glucose, patients should be strongly advised to limit or avoid its consumption. They should be specifically warned about the risk of delayed hypoglycemia.[50]
• Driving and Operating Machinery: Patients must be cautioned that hypoglycemia can severely impair concentration and reaction time. They should be advised to check their blood glucose before driving and to avoid driving or operating heavy machinery if they feel hypoglycemic or if they suffer from hypoglycemia unawareness.[50]

Synthesis and Clinical Perspective

Insulin degludec/liraglutide (Xultophy® 100/3.6) has emerged as a potent and rational therapeutic option for the management of type 2 diabetes mellitus. By co-formulating an ultra-long-acting basal insulin with a GLP-1 receptor agonist, it addresses multiple pathophysiological defects of the disease through complementary mechanisms of action.

The extensive evidence from the DUAL clinical trial program robustly supports its efficacy. The combination consistently delivers superior or non-inferior HbA1c​ reductions compared to a wide range of standard-of-care comparators, including its monocomponents, uptitrated basal insulin, and even intensive basal-bolus therapy. This potent glycemic control is achieved alongside significant and clinically meaningful advantages in safety and tolerability. Compared to traditional insulin intensification strategies, insulin degludec/liraglutide is associated with a markedly lower risk of hypoglycemia and a favorable body weight profile, often resulting in modest weight loss rather than the weight gain typically seen with insulin. These attributes, combined with the simplicity of a single daily injection, address key patient-centric barriers that often hinder adherence to more complex regimens.

The ideal candidate for insulin degludec/liraglutide is a patient with T2DM who is not at their glycemic goal on either basal insulin or a GLP-1 RA alone. It is particularly well-suited for a patient on basal insulin who requires intensification but for whom the risks of hypoglycemia and weight gain, or the burden of a multi-injection basal-bolus regimen, are significant concerns. It also serves as an excellent intensification option for patients failing GLP-1 RA therapy who require the added glycemic power of a basal insulin.

Despite its advantages, the therapy has limitations. The fixed-ratio design precludes the independent titration of the insulin and GLP-1 RA components, making it unsuitable for patients who may require disparate adjustments of each. The maximum daily dose of 50 units of insulin degludec may be insufficient for patients with severe insulin resistance. Furthermore, the FDA Boxed Warning regarding the potential risk of thyroid C-cell tumors necessitates careful patient selection, contraindicating its use in those with a personal or family history of MTC or MEN 2, and requires a thorough risk-benefit discussion with all patients.

In conclusion, insulin degludec/liraglutide represents a significant advancement in the T2DM therapeutic armamentarium. It offers a powerful, evidence-based strategy for treatment intensification that effectively balances potent glycemic lowering with an improved safety profile and a simplified regimen. For the appropriately selected patient, it provides a valuable pathway to achieve glycemic targets while minimizing treatment burden and the adverse effects that have long complicated insulin therapy. Its use demands a thoughtful clinical assessment, a comprehensive understanding of its risk-benefit profile, and a commitment to thorough patient education.

Works cited

1. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications, accessed August 18, 2025, https://diabetesjournals.org/clinical/article/36/2/149/32811/Safety-and-Efficacy-of-Insulin-Degludec
2. Xultophy (insulin degludec and liraglutide) FDA Approval History - Drugs.com, accessed August 18, 2025, https://www.drugs.com/history/xultophy.html
3. Xultophy Injection (Insulin Degludec and Liraglutide): Side Effects ..., accessed August 18, 2025, https://www.rxlist.com/xultophy-drug.htm
4. Insulin degludec/liraglutide - Wikipedia, accessed August 18, 2025, https://en.wikipedia.org/wiki/Insulin_degludec/liraglutide
5. Insulin degludec and liraglutide Uses, Side Effects & Warnings, accessed August 18, 2025, https://www.drugs.com/mtm/insulin-degludec-and-liraglutide.html
6. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) | NICE, accessed August 18, 2025, https://www.nice.org.uk/guidance/esnm60/resources/type-2-diabetesinsulin-degludecliraglutide-xultophy-1502681098503877
7. Use and effectiveness of a fixed‐ratio combination of insulin degludec/liraglutide (IDegLira) in a real‐world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5873250/
8. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5306117/
9. Xultophy 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy - FirstWord Pharma, accessed August 18, 2025, https://firstwordpharma.com/story/4381498
10. Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial, accessed August 18, 2025, https://journalforclinicalstudies.com/xultophy-reported-better-option-basal-bolus-insulin-therapy-manage-type-2-diabetes-participants-dual-vii-clinical-trial/
11. Xultophy | European Medicines Agency (EMA), accessed August 18, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy
12. www.novocare.com, accessed August 18, 2025, https://www.novocare.com/diabetes/products/xultophy10036/about-xultophy.html#:~:text=The%20most%20common%20side%20effects,for%20Xultophy%C2%AE%20100%2F3.6.
13. XULTOPHY 100/3.6 (insulin degludec and liraglutide) injection, for subcutaneous use - accessdata.fda.gov, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208583s021lbl.pdf
14. Xultophy 100/3.6: Side Effects and How to Manage Them - Healthline, accessed August 18, 2025, https://www.healthline.com/health/drugs/xultophy-side-effects
15. Xultophy® 100/3.6 Once-daily Injectable for Type 2 Diabetes - novoMEDLINK, accessed August 18, 2025, https://www.novomedlink.com/diabetes/products/treatments/xultophy10036.html
16. Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3411522/
17. Tresiba ® (insulin degludec) mechanism of protraction - novoMEDLINK, accessed August 18, 2025, https://www.novomedlink.com/diabetes/products/treatments/tresiba/about/how-tresiba-works.html
18. pmc.ncbi.nlm.nih.gov, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3411522/#:~:text=Its%20unique%20mechanism%20of%20action,that%20is%20over%2024%20hours.
19. Insulin degludec: overview of a novel ultra long-acting basal ... - PubMed, accessed August 18, 2025, https://pubmed.ncbi.nlm.nih.gov/23240573/
20. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: Advances in clinical research | Endocrinología y Nutrición (English Edition) - Elsevier, accessed August 18, 2025, https://www.elsevier.es/es-revista-endocrinologia-nutricion-english-edition--412-articulo-degludec-new-ultra-long-acting-basal-insulin-S2173509314000476
21. Liraglutide: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 18, 2025, https://go.drugbank.com/drugs/DB06655
22. Liraglutide - StatPearls - NCBI Bookshelf, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK608007/
23. Liraglutide (Victoza): The First Once-Daily Incretin Mimetic Injection For Type-2 Diabetes - PMC - PubMed Central, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2957743/
24. What is the mechanism of Liraglutide? - Patsnap Synapse, accessed August 18, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-liraglutide
25. Saxenda® (liraglutide) Injection 3 mg Mechanism of Action - novoMEDLINK, accessed August 18, 2025, https://www.novomedlink.com/obesity/products/treatments/saxenda/about/how-saxenda-works.html
26. Insulin Degludec/Liraglutide - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5551637/
27. Introduction - Clinical Review Report: Insulin degludec and liraglutide injection (Xultophy) - NCBI Bookshelf, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554829/
28. Figure 10, Change in Body Weight With IDegLira vs. IGlar U100 Across Categories of Baseline Body Mass Index in DUAL V Trial - Clinical Review Report: Insulin degludec and liraglutide injection (Xultophy) - NCBI, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554821/figure/cl.app4.fig9/
29. Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes, accessed August 18, 2025, https://www.prnewswire.com/in/news-releases/xultophy-reduces-cardiovascular-risk-factors-in-people-with-type-2-diabetes-644202383.html
30. Safety Evaluations Dosing Inclusion Criteria Primary Endpoint Secondary Endpoints - MultiVu, accessed August 18, 2025, https://www.multivu.com/players/English/7542051-xultophy-phase-3b-study/links/7542051-GLOBAL-DUAL-V-clinical-trial.pdf
31. References - Clinical Review Report: Insulin degludec and liraglutide injection (Xultophy) - NCBI Bookshelf, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554826/
32. Insulin Degludec and Liraglutide Improves Add-on T2D Therapy in DUAL IX Trial - HCPLive, accessed August 18, 2025, https://www.hcplive.com/view/insulin-degludec-and-liraglutide-improves-addon-t2d-therapy-in-dual-ix-trial
33. Significant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications - PR Newswire, accessed August 18, 2025, https://www.prnewswire.com/in/news-releases/significant-blood-sugar-improvement-with-xultophy-compared-to-insulin-glargine-u-100-when-used-as-add-686345141.html
34. How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7566936/
35. Executive Summary - Clinical Review Report: Insulin degludec and liraglutide injection (Xultophy) - NCBI Bookshelf, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554835/
36. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®) - ClinicalTrials.gov, accessed August 18, 2025, https://clinicaltrials.gov/study/NCT01179048
37. Cost & Coverage | Xultophy® 100/3.6 (insulin degludec and liraglutide) injection, accessed August 18, 2025, https://www.novomedlink.com/diabetes/products/treatments/xultophy10036/cost-coverage.html
38. Xultophy (liraglutide/insulin degludec) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 18, 2025, https://reference.medscape.com/drug/xultophy-liraglutide-insulin-degludec-1000105
39. Xultophy 100/3.6 Dosage Guide - Drugs.com, accessed August 18, 2025, https://www.drugs.com/dosage/xultophy-100-3-6.html
40. Xultophy 100/3.6 Dosage: Form, Strength, How to Use, and More - Healthline, accessed August 18, 2025, https://www.healthline.com/health/drugs/xultophy-dosage
41. Xultophy 100/3.6: Dosage, side effects, alternatives, and more - Medical News Today, accessed August 18, 2025, https://www.medicalnewstoday.com/articles/drugs-xultophy
42. Xultophy 100 units/mL + 3.6 mg/mL solution for injection - Summary of Product Characteristics (SmPC) - (emc), accessed August 18, 2025, https://www.medicines.org.uk/emc/product/3469/smpc
43. XULTOPHY 100/3.6, insulin degludec - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208583s008s010s011lbl.pdf
44. Dosing & Administration | Xultophy® 100/3.6 (insulin degludec and liraglutide) injection, accessed August 18, 2025, https://www.novomedlink.com/diabetes/products/treatments/xultophy10036/dosing-administration.html
45. Therapy Initiation and Titration - Diabetes Toolbox, accessed August 18, 2025, https://diabetestoolbox.ca/pdf/Xultophy_en.pdf
46. Reference ID: 4016640 This label may not be the latest approved by FDA. For current labeling information, please visit https:// - accessdata.fda.gov, accessed August 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208583s000lbl.pdf
47. How to Take Xultophy® 100/3.6 (insulin degludec and liraglutide) injection 100 units/mL and 3.6 mg/mL - NovoCare, accessed August 18, 2025, https://www.novocare.com/diabetes/products/xultophy10036/taking-xultophy.html
48. Xultophy, INN-insulin degludec/liraglutide - European Medicines Agency, accessed August 18, 2025, https://www.ema.europa.eu/en/documents/product-information/xultophy-epar-product-information_en.pdf
49. About Xultophy® 100/3.6 (insulin degludec and liraglutide) injection ..., accessed August 18, 2025, https://www.novocare.com/diabetes/products/xultophy10036/about-xultophy.html
50. PATIENT MEDICATION INFORMATION - Novo Nordisk Canada, accessed August 18, 2025, https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/xultophy-en-consumer-info-15-sep-2023.pdf
51. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION XULTOPHY® insulin degludec + liraglutide injection 100 units/mL + 3., accessed August 18, 2025, https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Xultophy%20PM%20EN_Marketed_13%20November%202020.pdf
52. Using Your Xultophy Pen - FV Health, accessed August 18, 2025, https://www.fvfiles.com/524855.pdf
53. Xultophy, INN-insulin degludec/liraglutide, accessed August 18, 2025, https://www.medicines.org.uk/emc/files/pil.3469.pdf
54. Missed a dose (or more) of your GLP-1 medication? Here's what to do | UCLA Health, accessed August 18, 2025, https://www.uclahealth.org/news/article/missed-dose-or-more-your-glp-1-medication-heres-what-do
55. www.medicalnewstoday.com, accessed August 18, 2025, https://www.medicalnewstoday.com/articles/drugs-xultophy#:~:text=This%20drug%20has%20a%20boxed%20warning%20for%20thyroid%20tumors%20and,of%20thyroid%20tumors%20in%20animals.
56. A Common Diabetes Treatment Leads to Diagnosis of a Rare Thyroid Cancer | NYU Langone News, accessed August 18, 2025, https://nyulangone.org/news/common-diabetes-treatment-leads-diagnosis-rare-thyroid-cancer
57. Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists? - Cleveland Clinic Journal of Medicine, accessed August 18, 2025, https://www.ccjm.org/content/ccjom/82/3/142.full.pdf
58. insulin degludec and liraglutide - St. Luke's, accessed August 18, 2025, https://www.stlukesonline.org/health-services/health-information/healthwise/2017/06/27/13/14/insulin-degludec-and-liraglutide
59. Insulin Degludec and Liraglutide | Memorial Sloan Kettering Cancer Center, accessed August 18, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/insulin-degludec-and-liraglutide
60. Side Effects of Xultophy (insulin degludec and liraglutide injection) - MedicineNet, accessed August 18, 2025, https://www.medicinenet.com/side_effects_of_xultophy/side-effects.htm
61. Side effects of Tresiba ® (insulin degludec) and other hypoglycemia data - novoMEDLINK, accessed August 18, 2025, https://www.novomedlink.com/diabetes/products/treatments/tresiba/safety-trials-and-hypoglycemia/switch-2-study.html
62. Xultophy (insulin degludec / liraglutide): Uses, Side Effects, Dosage & More - GoodRx, accessed August 18, 2025, https://www.goodrx.com/xultophy/what-is
63. Insulin Degludec / Liraglutide Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 18, 2025, https://www.drugs.com/sfx/insulin-degludec-liraglutide-side-effects.html
64. Xultophy (insulin degludec/liraglutide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 18, 2025, https://www.webmd.com/drugs/2/drug-172911/xultophy-100-3-6-subcutaneous/details
65. Insulin degludec and liraglutide (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed August 18, 2025, https://www.mayoclinic.org/drugs-supplements/insulin-degludec-and-liraglutide-subcutaneous-route/description/drg-20313078
66. Xultophy and Alcohol/Food Interactions - Drugs.com, accessed August 18, 2025, https://www.drugs.com/food-interactions/insulin-degludec-liraglutide,xultophy.html
67. Victoza, Saxenda (liraglutide) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 18, 2025, https://reference.medscape.com/drug/victoza-saxenda-liraglutide-999449
68. Xultophy 100-3.6 Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed August 18, 2025, https://www.wellrx.com/xultophy-100-36/lifestyle-interactions/
69. Tresiba and Victoza Interactions Checker - Drugs.com, accessed August 18, 2025, https://www.drugs.com/drug-interactions/tresiba-with-victoza-3693-17546-3189-14350.html
70. Xultophy Interactions Checker - Drugs.com, accessed August 18, 2025, https://www.drugs.com/drug-interactions/insulin-degludec-liraglutide,xultophy.html
71. Insulin degludec/liraglutide Interactions - Drugs.com, accessed August 18, 2025, https://www.drugs.com/drug-interactions/insulin-degludec-liraglutide.html
72. Liraglutide (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed August 18, 2025, https://www.mayoclinic.org/drugs-supplements/liraglutide-subcutaneous-route/description/drg-20073828
73. Insulin degludec Interactions - Drugs.com, accessed August 18, 2025, https://www.drugs.com/drug-interactions/insulin-degludec.html
74. These highlights do not include all the information needed to use XULTOPHY® 100/3.6 safely and effectively. See full prescribing information for XULTOPHY 100/3.6. XULTOPHY 100/3.6 (insulin degludec and liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2016 - DailyMed, accessed August 18, 2025, https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=21335fe4-d395-4501-ac2a-2f20d7520da9